Novartis Sticks With Heart Of Pipeline: Growth Is In Cardio-Metabolic Sector
Executive Summary
Novartis will continue to focus on the cardiovascular-metabolic segment in the near term with filings planned for new diabetes and hypertension therapies and line-extensions for its existing agents
You may also be interested in...
Novartis Has Proof Of Concept For New R&D Model, And NMEs To Show It
Novartis showed off its new drug pipeline for the first time in three years Nov. 19, but the R&D day was as much about vindicating the novel research strategy it rolled out in 2002 as it was previewing the work in process
Novartis Has Proof Of Concept For New R&D Model, And NMEs To Show It
Novartis showed off its new drug pipeline for the first time in three years Nov. 19, but the R&D day was as much about vindicating the novel research strategy it rolled out in 2002 as it was previewing the work in process
Novartis Has Proof Of Concept For New R&D Model, And NMEs To Show It
Novartis showed off its new drug pipeline for the first time in three years Nov. 19, but the R&D day was as much about vindicating the novel research strategy it rolled out in 2002 as it was previewing the work in process.